Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | VSV-GP154 |
Trade Name | |
Synonyms | VSV GP154|VSVGP154 |
Drug Descriptions |
VSV-GP154 is a vesicular stomatitis virus (VSV) viral vector-based cancer vaccine containing pancreatic adenocarcinoma patient-derived tumor-associated antigen peptides, which preferentially replicates in tumor cells expressing KRAS G12V or KRAS G12D, potentially resulting in tumor cell killing (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C199669 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ATP150 + ATP152 + Ezabenlimab + VSV-GP154 | ATP150 ATP152 Ezabenlimab VSV-GP154 | 0 | 1 |
ATP150 + ATP152 + VSV-GP154 | ATP150 ATP152 VSV-GP154 | 0 | 1 |
VSV-GP154 | VSV-GP154 | 0 | 0 |